Core Viewpoint - Jiangxi Jindalai Environmental Protection Co., Ltd. plans to invest 30 million RMB in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake, aiming to optimize its industrial structure and explore new growth opportunities in the medical robotics sector [2][3][16]. Investment Overview - The investment amount is set at 30 million RMB, with 195.86895 thousand RMB allocated for the subscription of new registered capital and the remaining 28.04131 million RMB added to the capital reserve [3]. - The investment has been approved through internal procedures and does not require further approval from the board or shareholders, nor does it constitute a major asset restructuring or related party transaction [2][4]. Target Company Information - Zhongke Hongtai specializes in the research, production, and sales of medical robotics technology and systems, founded by a team of experts led by Professor Hou Zengguang [5]. - The company has a strong research background, having undertaken significant projects in the vascular interventional surgery robot field since 2008, and holds over 100 independent intellectual property rights [5]. - The target company is recognized as a national high-tech enterprise and has products in the special review process for innovative medical devices by the National Medical Products Administration [5][6]. Financial and Operational Aspects - The investment will be made in cash from the company's own funds, and the funds will be used for technology research and development, market promotion, and daily operations [12][16]. - The target company has completed 16 clinical trials for its multi-channel vascular interventional surgery robot, which is currently in the process of accelerating its clinical trials [6]. Strategic Impact - This investment aligns with the company's strategy to diversify into the healthcare sector, particularly in medical devices and biomanufacturing, enhancing its risk resilience and creating new profit growth points [16]. - The investment is expected to strengthen the company's competitive edge and influence in the market, promoting sustainable development without affecting its daily operations or shareholder interests [16].

Core Viewpoint - Jindalai (688057) plans to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake, indicating a strategic move towards the medical robotics sector [1] Group 1: Investment Details - The investment amount is 30 million yuan, which will be used to increase the capital of Zhongke Hongtai [1] - After the transaction, Jindalai will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Company Strategy - Jindalai expresses optimism about the development prospects of medical robotics technology and systems, which are part of the national strategic emerging industries [1] - The company aims to gradually optimize its industrial structure and seek new opportunities for future growth, enhancing its risk resistance and cultivating new profit growth points [1]

Core Viewpoint - Jindalai (688057.SH) plans to invest 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake, aiming to optimize its industrial structure and seek new growth opportunities [1] Group 1: Investment Details - The investment will be made using the company's own funds amounting to 30 million yuan [1] - After the investment, Jindalai will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Company Background - Zhongke Hongtai specializes in the research, production, and sales of medical robot technology and systems [1] - The company was incubated by the Institute of Automation, Chinese Academy of Sciences, and is led by a team of experts including Professor Hou Zengguang [1] - Since 2008, the founding team has undertaken over 10 major projects, including the first domestic 863 program for vascular interventional surgical robots [1] Group 3: Financial Status and Purpose of Investment - Zhongke Hongtai is currently not profitable [1] - The investment aims to enhance the company's risk resistance and cultivate new profit growth points [1] - Funds from the investment will be allocated for technology research and development, market promotion, and daily operations [1]

格隆汇12月21日丨金达莱(688057.SH)公布，公司基于对医疗机器人技术与系统的研发及应用等国家战 略性新兴行业发展前景看好，拟逐步优化公司产业结构，为未来发展寻找新的产业机会，以提高公司的 抗风险能力，培育新的利润增长点。公司拟以人民币3000万元向中科鸿泰增资，其中：195.86895万元 用于认购中科鸿泰195.86895万元的新增注册资本，剩余2804.13105万元计入资本公积。本次交易完成 后，公司将持有中科鸿泰10.00%的股权。 ...

中科鸿泰主要从事医疗机器人技术与系统的研发、生产及销售，是中国科学院自动化研究所孵化设立的 科技成果转化企业，由IEEE Feow、杰青、万人领军人才专家侯增广教授领衔的科学家团队创办。中科 鸿泰创始团队自2008年起，承担血管介入手术机器人国内首个863计划等10余项重大项目，是国内血管 介入手术机器人领域先行者。中科鸿泰目前尚未盈利。 人民财讯12月21日电，金达莱(688057)12月21日公告，公司拟以3000万元向北京中科鸿泰医疗科技有限 公司(简称"中科鸿泰")增资，交易完成后，公司将持有中科鸿泰10%的股权。 ...

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a strategic investment in Zhongke Hongtai Medical Technology Co., Ltd. [1] Group 1: Investment Details - The company intends to invest 30 million yuan in Zhongke Hongtai, with 1.9586895 million yuan allocated for subscribing to the new registered capital and the remaining 28.0413105 million yuan added to capital reserves [1] - Upon completion of the transaction, the company will hold a 10% equity stake in Zhongke Hongtai [1] Group 2: Product Advantages - Zhongke Hongtai's self-developed multi-channel vascular intervention surgical robot features significant advantages, including a bionic design that allows simultaneous rotation and pushing of guidewires [1] - The dual-channel design enables the operation of two guidewires and two balloon/stent catheters simultaneously, along with force feedback functionality [1] - The surgical robot can perform remote surgeries, provide full-process robotic assistance, and collect data, surpassing existing industry standards [1] Group 3: Strategic Goals - The core team of Zhongke Hongtai possesses deep technical expertise and original research capabilities, offering differentiated innovation and technological breakthroughs [2] - The investment aims to expand the company's business, enhance profitability, and improve overall competitiveness and influence, promoting sustainable development [2]

Core Viewpoint - The company, Jindalai (688057.SH), is optimistic about the development prospects of medical robotics technology and plans to optimize its industrial structure to enhance risk resistance and cultivate new profit growth points through a capital increase in Beijing Zhongke Hongtai Medical Technology Co., Ltd. [1][2] Group 1: Investment Details - The company intends to invest 30 million yuan in Zhongke Hongtai, with 1.9586895 million yuan allocated for subscribing to the new registered capital and the remaining 28.0413105 million yuan added to the capital reserve [1] - After the transaction, the company will hold a 10% stake in Zhongke Hongtai [1] Group 2: Product Advantages - Zhongke Hongtai's self-developed multi-channel vascular interventional surgical robot features significant advantages, including bionic design for simultaneous wire rotation and pushing operations, dual-channel design for operating two wires and two balloon/stent catheters simultaneously, and force feedback functionality [1] - The surgical robot can perform remote surgeries, full-process robotic assistance, and data collection, surpassing existing industry standards [1] Group 3: Strategic Goals - The core team of Zhongke Hongtai possesses deep technical expertise and original research and development capabilities, offering differentiated innovation and technological breakthroughs [2] - The investment aims to expand the company's business, enhance profitability, improve overall competitiveness and influence, and promote sustainable development [2]

深圳机器人产业发展有多快、有多燃？答案或许就藏在一家成立仅 7 年的本土企业身上——元化智能科技 （深圳）有限公司。这家专注于高端专科智能医疗装备研发的企业，不仅实现了全产品线的自主研发，更在 2025 年创下一年斩获 12 张国内外医疗器械注册证的亮眼成绩，吹响了挺进全球市场的号角。 骨圣元化机器人（深圳）有限公司 Yuanhua Orthopaedic Robotics (Shenzhen) Co., Ltd 通过持续自主研发，元化智能骨科手术 产品矩阵持续完善， 2025 年内累计取得 12 项注册认证 的市场准入 覆盖 手术机器人 "设备 - 软件 - 耗材 - 康复"全流程 。在 核心设备方面 ，锟铻 ® 五合一全骨科手术机器人 "骨科手术导航定位系统 YH-ORTH "（国械注准 20253012144 ）获国家药监局三类医疗器械注册证，实现 脊柱与关节手术全覆盖；"关节置换手术导航定位系统 KUNWU-SP "（国械注准 20253011140 ）与自研机械 臂膝关节手术系统" YuanBOT-HX200 "（国械注准 20253012602 ）相继获批，进一步巩固在关节手术领域 的领先地位。 ...

Core Viewpoint - MicroPort Robotics-B (02252) has been included in the newly launched Hong Kong Stock Exchange's Tech 100 Index, reflecting strong market recognition of its technological innovation and growth potential in the biotech sector [1] Group 1: Stock Performance - The stock price of MicroPort Robotics-B rose over 6% in early trading, currently up 4.48% at HKD 21, with a trading volume of HKD 44.38 million [1] Group 2: Market Recognition - The inclusion in the Tech 100 Index signifies the capital market's high recognition of the company's leadership position and long-term growth potential in the biotech industry [1] Group 3: Order Growth - As of October 8, 2023, MicroPort Robotics has received over 170 surgical robot orders, an increase from 150 orders at the end of August [1] - Morgan Stanley has raised the installation forecast for MicroPort Robotics from 84 units to 105 units for the year, driven by strong overseas growth and the assumption that orders can be converted to sales within a quarter [1] Group 4: Financial Projections - The company is expected to see an improvement in gross margin by 1 to 1.5 percentage points due to a higher installation base and product mix enhancement [1]

各位专家学者，朋友们: 会议主题 02 本次大会以" 京珠共邀汇湾区·医工融合启未来 "为主题，旨在搭建一个汇聚政府、协会、医院、高校、科研机构、 投融资机构及企业的全方位资源对接平台，推动医工融合在生物医药、智能诊疗、手术机器人、AI内镜、微纳材料、数 字疗法等前沿领域的深度合作与成果转化。 会议组织机构 03 指导单位： 中国医药卫生文化协会 主办单位： 北京理工大学（珠海） 中国医药卫生文化协会医工融合分会 联合主办： 广东真健康医疗科技开发股份有限公司 在"健康中国2030"战略的引领下，医工融合正成为驱动高端医疗装备自主突破、生物医药创新发展、催 生新质生产力的关键引擎。珠海，作为粤港澳大湾区战略支点，叠加"三区"政策红利，已汇聚高端人才、顶尖 医疗、科研与产业资源，具备打造国家级医工融合高地的独特优势。 为积极响应广东省打造万亿级生物医药与健康产业集群的战略部署，促进粤港澳大湾区医工融合高质量 发展，在中国医药卫生文化协会指导下，中国医药卫生文化协会医工融合分会联合北京理工大学、北京理工大 学（珠海）、珠海市人民医院等机构，定于 2025年12月26日(周五)至28日(周日) ，在 广东·珠海 隆 ...